Status:
RECRUITING
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Collaborating Sponsors:
Shanghai Public Health Clinical Center
Huashan Hospital
Conditions:
MDR-TB
Immunotherapy
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
Detailed Description
The emergence and prevalence of drug-resistant TB in recent years has made TB control more challenging, and MDR-TB is more serious type of drug-resistance TB with a cure rate of just over half, even w...
Eligibility Criteria
Inclusion Criteria:
- RR-TB/MDR-TB (resistant to at least isoniazid and rifampicin).
- Poor efficacy of the original treatment regimen or no response to treatment or less than 4 effective drugs.
Exclusion Criteria:
- Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc.
- Test confirms poor response to ZOL and IL-2 stimulation.
Key Trial Info
Start Date :
August 3 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 3 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05493267
Start Date
August 3 2022
End Date
August 3 2027
Last Update
August 10 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Pulmonary Hospital, Shanghai, China
Shanghai, China, 200433
2
Shanghai Pulmonary Hospital
Shanghai, China